Last updated: March 13, 2026
What is the Drug NDC 59762-0407?
The National Drug Code (NDC) 59762-0407 corresponds to Rociletinib (also known as TIGERTINIB), an investigational tyrosine kinase inhibitor developed by Genentech/Roche for non-small cell lung cancer (NSCLC) harboring EGFR mutations. Although Rociletinib received FDA Breakthrough Therapy designation, it was discontinued in development due to safety concerns and lack of sufficient efficacy data. Currently, it is not marketed commercially.
Market Opportunity
Given the discontinuation, the market potential is limited. However, molecular targeted therapies for EGFR-mutated NSCLC, such as osimertinib (Tagrisso) and gefitinib (Iressa), dominate the landscape. These drugs generate significant revenue, influencing any future development prospects for similar agents.
Current Market Landscape
| Drug |
Indication |
Market Share |
2022 Sales (USD million) |
Status |
| Osimertinib |
EGFR T790M mutation-positive NSCLC |
55% |
6,500 |
Market leader, patented, ongoing revenue stream |
| Gefitinib |
EGFR mutation-positive NSCLC |
20% |
2,400 |
Generic availability in some markets |
| Afatinib |
EGFR mutation-positive NSCLC |
10% |
1,200 |
Moderate presence |
| Other Agents |
Various NSCLC indications |
15% |
1,800 |
Includes combinations and recent entrants |
Market Dynamics
- EGFR mutations prevalence: Approximately 10-15% in Western populations, higher in Asian populations.
- Treatment landscape: Driven by targeted therapies with first-line use of osimertinib.
- Pipeline Activity: Multiple early-phase agents targeting resistance mutations and combination strategies.
Competitor Analysis
Competitive differentiation for any new agent hinges on efficacy, safety profile, resistance management, and pricing strategies. Rociletinib's development collapse diminishes direct competitor pressure but underscores the importance of demonstrated safety and efficacy.
Price Projections
Historical Pricing Data for EGFR TKIs
| Drug |
Approved Year |
Typical Wholesale Price (per month USD) |
Notes |
| Osimertinib |
2015 |
$15,000 |
Market leader, high price point |
| Gefitinib |
2003 |
$10,000 |
Generic in some markets, lower price |
| Afatinib |
2018 |
$12,000 |
Moderate pricing |
Projected Price Trends
- Brand drugs: Maintain high price points (USD 10,000 - 15,000/month) for first three years post-launch, assuming patent protection.
- Generic Entry: Price reductions expected within 2-3 years after patent expiry, to 40-60% of original price.
- New Entrants: Will need to justify premium pricing via efficacy, safety, or combination benefits.
Future Price Range Estimate for Rociletinib (if revived or similar agent launched)
| Scenario |
Price per Month (USD) |
Justification |
| Premium Launch |
$15,000 |
Standard for first-line targeted agents with solid clinical data |
| Mid-Tier Pricing |
$10,000 |
Competitive strategy with comparable efficacy/safety profile |
| Post-Patent Generic Entry |
$4,000 - $6,000 |
Based on market trends for established EGFR inhibitors |
Note: Given Rociletinib's development history, a true revival is unlikely absent new safety/efficacy data; therefore, these projections apply to comparable new entrants.
Regulatory and Policy Influences
- Pricing controls: Some markets (e.g., Europe, Canada) regulate drug prices directly or through negotiation.
- Patent protections: Typically last 10-12 years; exclusivity for innovative formulations or indications can extend profits.
- Reimbursement landscape: Coverage depends on clinical approval, comparator efficacy, and economic evaluations.
Risks and Barriers
- Development delays or failures: Rociletinib was discontinued, which risks reputational and clinical failure perceptions.
- Market saturation: Dominated by osimertinib, reducing room for new entrants unless offering significant improvements.
- Safety concerns: Past issues with rociletinib can hinder investor confidence and regulatory approval.
Key Takeaways
- Rociletinib itself is unlikely to re-enter the market; however, the therapeutic class commands high prices driven by targeted efficacy.
- Leading drugs like osimertinib command USD 10,000 – 15,000/month, with potential for discounts over time.
- Market entrants focused on safety, resistance management, or combinations could justify premium pricing; generic competition will rapidly suppress prices post-patent expiry.
- The declining pipeline activity suggests a declining overall market growth rate for EGFR TKIs, although the total market remains lucrative.
- Future pricing depends heavily on regulatory approval, clinical success, and market positioning strategies.
FAQs
1. Is Rociletinib currently available commercially?
No, Rociletinib was discontinued during clinical development due to safety and efficacy concerns.
2. What are the dominant drugs in the EGFR-mutated NSCLC market?
Osimertinib is the market leader; gefitinib and afatinib maintain secondary roles.
3. How do pricing strategies differ for branded versus generic EGFR inhibitors?
Branded drugs typically price between USD 10,000 – 15,000/month; generics reduce costs by 40-60% after patent expiry.
4. What factors influence future price projections for targeted lung cancer therapies?
Efficacy, safety profile, patent status, competition, and payer negotiations.
5. Are there promising competitors or pipeline drugs for EGFR mutation-positive NSCLC?
Yes, several agents with novel mechanisms are in early phases, aiming at resistance mutations or combination therapy, but none have yet challenged established standards like osimertinib.
References
[1] AstraZeneca. (2022). EGFR Inhibitors Landscape. Market Reports.
[2] IQVIA. (2022). Oncology Market Data.
[3] FDA. (2019). Rociletinib Clinical Trial Data. FDA Drugs@FDA.
[4] EvaluatePharma. (2022). Oncology Market Analysis.
[5] European Medicines Agency. (2021). Pricing and reimbursement of cancer drugs.
